I
specialize in:
Acupuncture
Athens:
2080 Prince Avenue
Athens Georgia
(706) 201-5605
Contact Me
acupuncture athens |
Acupuncture Research
WOMEN'S HEALTH
Effects of unkei-to, an herbal medicine,
on endocrine function and Effects of unkei-to, an herbal medicine,
on endocrine function and ovulation in women with high basal
levels of luteinizing hormone secretion.
J Reprod Med. 2001 May;46(5):451-6
Ushiroyama T, Ikeda A, Sakai M, Hosotani T, Suzuki Y, Tsubokura
S, Ueki M.
Department of Obstetrics and Gynecology, Osaka Medical College,
2-7 Daigaku-machi, Takatsuki, Osaka 569-8686, Japan. gyn003@poh.osaka-med.ac.jp
OBJECTIVE: To treat anovulatory women with high plasma LH
levels with unkei-to.
STUDY DESIGN: A total of 100 patients with polycystic ovary
syndrome (n = 38) or non-polycystic ovary syndrome (n = 62)
were allocated randomly into two groups. Endocrine levels
(FSH, LH and estradiol), follicle growth and response to unkei-to
were compared for 52 subjects in the unkei-to group and 48
subjects in the control group.
RESULTS: Unkei-to induced significant decreases in plasma
LH in polycystic ovary syndrome and non-polycystic ovary syndrome
with high LH levels. Plasma estradiol levels increased significantly
(43.5%) in eight weeks of treatment with unkei-to. Significant
development of the dominant follicle was also observed in
patients treated with unkei-to. When women suffering from
ovulatory failure or irregular menstruation and having high
plasma LH concentration were treated with unkei-to for eight
weeks, a reduction in the serum LH level of at least 1 SD
from baseline was noted in 45.5% of polycystic ovary syndrome
patients and in 80.0% of non-polycystic ovary syndrome patients.
The mean rate of reduction of serum LH was 22.2 +/- 35.7%
in polycystic ovary syndrome patients and 49.7 +/- 15.3% in
non-polycystic ovary syndrome patients. This reduction was
significant in the non-polycystic ovary syndrome patients
(P = .030). The rate of menstrual cycle improvement, including
successful ovulation, was 50.0% in the polycystic ovary syndrome
group and 60.0% in the non-polycystic ovary syndrome group,
with no significant difference between the two groups.
|
|